Healthcare resource utilization (HCRU) and costs in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective observational cohort study in England

Résumé fourni par la source

Background: Population-based data on EGPA economic burden are limited. Aim: To assess all-cause HCRU and costs of managing patients with EGPA versus severe uncontrolled asthma (SUA). Methods: Primary care data in England from the Clinical Practice Research Datalink Aurum database, with linkage to Hospital Episode Statistics inpatient, outpatient and emergency department records, were analysed. Patients with an EGPA diagnosis in 2006–2019 and ≥1 year of data before diagnosis (index date [ID]) were included and matched with patients with SUA without EGPA. Follow-up was from ID until deregistration, last data collection from GP, death, or study end. HCRU and associated costs were assessed. Results: 486 patients with EGPA and 1005 patients with SUA were matched. Annual all-cause HCRU rates during follow-up were higher in the EGPA cohort versus the SUA cohort for all types of care. Annualized total HCRU-associated costs (confidence interval [CI] 95%) were higher in the EGPA cohort (£13977.88 [12021.01, 15934.74]) versus the SUA cohort (£3570.73 [3325.91, 3815.56]) with a cost ratio (CI 95%) of 4.08 (3.62, 4.60); p<0.0001 (Table). Conclusion: Patients with EGPA had higher HCRU rates and annualized costs than patients with SUA, highlighting a need for integrated service provision and EGPA care pathways. erj;66/suppl_69/PA3642/F1 F1 F1